**Table 3.**

*Analysis of variance (ANOVA) table for t-period, t-treatment crossover design.*


**Table 4.**

*Design 1 A comparison of ANOVA for parallel group design and 2-treatment, 2-period crossover design with n subjects.*


#### **Table 5.**

*Design 2A comparison of ANOVA for parallel group design and 2-treatment, 2-period crossover design with n subjects.*

sense that the regulatory authorities should control the consumer's risk and let the pharmaceutical company decide how much manufacturer's risk they are willing to accept. According to FDA guidelines for bioavailability studies state that "Products whose rate and extent of absorption differ by 20% or less are generally bioequivalent." The main object of bioequivalence studies is not in testing the null hypothesis of equality but to assess the difference between in two treatments groups and bioequivalence studies of two formulations is concluded that the difference is within 20% of the reference mean.
